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ABSTRACT
The potency of live rubella virus vaccine is usually determined by the microtitration method using in vitro cytopathic effect (CPE) with
rabbit kidney epithelial (RK-13) cell culture. However, it is difficult to identify the rubella viral CPE through microscopic examination.
Therefore, developing a validated and accurate method for potency determination is important for the laboratories of the government and
vaccine manufacturers to ensure the effectiveness of rubella vaccination. In this study, we evaluated different culture conditions of RK-13
cells for the potency test of live rubella virus vaccine. We found that the RK-13 cells with the initial plating number of 13,000 per well of
96-well cell culture plate, supplied with 2% fetal bovine serum (FBS) could form and maintain a normal monolayer for 14 days when incubated at 33˚C. In addition, our results showed that the rubella viral CPEs are developed faster and simpler under 2% of serum concentration and at 33˚C. The results of validation analysis finally confirmed that the culture condition with plating number of 13,000 cells/well,
2% of serum concentration, and 33˚C incubating temperature achieve the most accurate and precise results for the CPE potency test of live
rubella virus vaccine.
Key words: cytopathic effect, live rubella vaccine, accuracy, precision and validation

INTRODUCTION
For many years, the live rubella virus vaccine has been
developed to protect people from rubella and congenital
rubella syndrome (CRS). The World Health Organization
(WHO) requirements for rubella vaccine were first formulated in 1976(1). Currently, the production of this vaccine is well
established with the live attenuated virus strains. These attenuated strains, including Cendehill, HPV-77, Takahashi,
Matsuura, and RA27/3, were initially licensed from 1969 to
1970(2). After a long term evaluation for vaccine safety and
efficacy, RA27/3 and Cendehill were recommended for use,
for the attenuated strains of live rubella vaccine and these two
kinds of rubella vaccines are widely available throughout the
world. The RA27/3 strain of rubella virus has been used since
1965. Compared with others, the RA27/3 strain developed by
Dr. S. A. Plotkin(3,4) was attenuated by additional passages of
cold adaptation in suitable cell cultures(5). The final passages
of cold adaptation were made first at 35˚C, then at 33˚C, and
finally at 30˚C. In addition, the results from evaluation of
vaccine efficacy showed that the vaccine recipients could
maintain the antibody titer against rubella virus in their sera
for 16-17 years after vaccination(5).
In Taiwan, the initially used live rubella virus vaccine
was RUDIVAX  (manufactured by Pasteur Merieux,
France) and it was licensed in 1976. There are five similar
products currently available on the Taiwan market (Table 1).
These vaccines are all manufactured with live attenuated
* Author for correspondence. Tel:02-26531232;
Fax:02-26531230; E-mail:dywang@nlfd.gov.tw

virus of the RA27/3 strain and harvested from MRC-5 or WI38 human fibroblast cell cultures. Live rubella virus vaccine
was widely introduced to Taiwan’s junior high school girls in
1984, and there were rare reported incidences of rubella during the period of 1988 to 1993(6). Additionally, to ensure the
vaccine efficacy against rubella, poliomyelitis, measles and
other infectious diseases in Taiwan, the National
Laboratories of Foods and Drugs (NLFD) of the Department
of Health (DOH) needs to safeguard the vaccine potency
through the lot-by-lot release process(6). For this reason, an
accurate and precise potency testing method is very important for evaluating the efficacy of live rubella virus vaccine.
A wide variety of different testing methods can be used
to quantify the virus content of live virus vaccine. There are
two main in vitro testing methods, the plaque formation unit
(PFU) and the CPE methods, for vaccine potency determination and validation(7). The introduction of the CPE method
with RK-13 cells for quantifying the rubella vaccine potency
usually made it possible to obtain more reliable results than
that of the PFU method in most situations(8, 9). However, the
CPE method still has some accuracy and precision problems
during the potency test(10-12). The major concern is that it is
not easy to identify the rubella viral CPE through microscopic examination. Plotkin and Beale indicated that rubella CPE
is either absent or mild under several culture systems(13).
Furthermore, we found the RA27/3 viral CPE looks like the
morphology of cell over-growth under the RK-13 cell culture
system. It is easy to make a mistake on rubella viral CPE
identification and raises the bias of potency results. Although
the vesicular somatitis virus (VSV) interference test has been
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Table 1. The currently available live rubella virus vaccines in Taiwan
Manufactures
Product
Pasteur Murieux Serum & Vaccines, France
RUDIVAX
Merck & Co., Inc., United States
MERUVAX II
Swiss Serum and Vaccine Institute Berne, Switzerland
RUBEATEN BERNA
SmithKline Beecham Biologicals, Belgium
ERVEVAX
The Research Foundation for Microbial Disease of
Rubella Virus Vaccine Live,
Osaka, Japan
Attenuated “BIKEN”

introduced to assist in recognizing the rubella viral CPE, this
interference method is more complicated and needs more
long-term incubation to obtain the results(14, 15). Most importantly, the VSV is classified into Biosafety Level 3 (BSL-3)
by the Centers for Disease Control and Prevention, U. S. A.
and should be handled under BSL-3 practices and facilities(16). Even a number of laboratory-adapted strains (Indina,
San Juan or Glascow) should be dealed with properly with
BSL-2 practices and facilities. Therefore, developing a faster,
safer, and more precise method is very important for potency
evaluation of live rubella virus vaccine.
In this study, we compared and evaluated different culture conditions of RK-13 cells for the potency test of live
rubella virus vaccine. We found that the RK-13 monolayer
supplemented with 2% FBS at 33˚C can maintain the normal
morphology during the testing period of 14 days. The evaluating results showed rubella viral CPE can be acquired faster
and more accurate at 33˚C incubation than at other temperature conditions. The results of validation analysis also confirmed that the 33˚C incubation can contribute the CPE
potency test of live rubella virus vaccine to achieve the most
accurate and precise results.

MATERIALS AND METHODS
I. Materials
Minimum essential medium (MEM) containing Earle's
salts, N-acetyl-L-alanyl-L-glutamine (Ac-ala-gln), and sodium bicarbonate and antibiotics (100x, lyophilized) were purchased from BIOCHROM KG (Berlin, German). Heat-inactivated and qualified fetal bovine serum (FBS) and trypsin/
ethylenediaminetetraacetic acid (trypsin /EDTA) solution
were purchased from Gibco BRL (Grand Island, NY, USA).
The ISOTONE II azide free balanced electrolyte solution
was supplied from Beckman Coulte, Inc. (Miami, FL, USA).
The 96-well cell culture plates, tissue culture flasks, and
other plastic accessories were from Corning/Costar (Nagog
Park Action, MA, USA). The VSV (ATCC VR-158) was purchased from the American Tissue Culture Collection
(ATCC). The live rubella virus vaccines were obtained from
the Center for Disease Control, Department of Health,
Taiwan, R.O.C.
II. Cell Culture and Cell Growth Test
RK-13 cells (ATCC CCL-37) were purchased from
ATCC. The master cell bank (MCB) and working cell bank

Virus Strain
RA27/3
RA27/3
RA27/3
RA27/3
RA27/3

Cell Substrate
MRC-5
WI-38
MRC-5
MRC-5
WI-38

Year Licensed
1976
1982
1982
1989
1995

(WCB) of RK-13 cells were established for routine potency
test. RK-13 cells were cultured in MEM supplemented with
5% FBS in a humidified incubator at 37˚C under 5% CO2
condition. The cells were subcultured with 1 x trypsin/EDTA
solution after confluence.
To evaluate the RK-13 culture conditions appropriate
for rubella virus infection, cells (1.3~1.5 × 104 per well) were
plated on the 96-well cell culture plate with 0.2 mL basal
MEM containing 0.5, 1, and 2% FBS. The cultures were
incubated at 30, 33, and 35˚C (the temperature point of
RA27/3 strain cold adaptation) for at least 14 days. The cells
were then harvested with trypsin/EDTA and re-suspended in
10 mL of ISOTONE II solution. The cell numbers were
determined by a Z1 Coulter Cell Counter (Beckman Coulter,
Inc., FL).
III. Rubella Potency Test and VSV Interference Test
The potency test of live rubella virus vaccine followed
the methods for potency testing of vaccines used in the World
Health Organization's (WHO) expanded program on immunization(17). It was conducted by the in vitro CPE microtitration method. Serial dilutions of vaccine samples were inoculated in rows of 10 wells of 96-well cell culture plates,
together with 0.1 mL of trypsinized RK-13 cell suspension
(1.5 × 104 cells per well). Then the plates were placed in
humidified CO2 incubators at different temperature setting
based on the RA27/3 strain cold adaptation, and the cultures
were incubated for 14 days. From Day 4, the CPE number in
each dilution was read and counted daily. At day 7, the media
of the RK-13 cultures were replaced with 0.2 mL of basal
MEM containing 2% FBS per well. At day 10, the media
were discarded and the cultures were inoculated with 100 to
300 cell culture infectious dose 50% (CCID50) VSV per well
of VSV. The cultures were further incubated at 33˚C and
examined microscopically about 24 hrs later. Those wells
where sufficient multiplication of rubella virus had taken
place were protected against the growth and cytopathic activity of VSV. At the end of the testing period, the CCID50 per
human dose was acquired from the Reed and Muench
method(18).
IV. Validation Analysis of Rubella Potency Test
In accordance with the validation analysis method of the
International Conference on Harmonization (ICH) guidelines(19, 20), all the potency data underwent validation analysis to evaluate the accuracy and precision of rubella potency
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test under different conditions. The SPSS statistic software
(SPSS Inc., Chicago, IL, USA) was used to proceed validation and evaluation.

RESULTS AND DISCUSSION
In order to obtain a stable culture system for RK-13 cells
to be infected with rubella virus, we examined several compositions of different serum concentrations and incubation

temperatures. We found that RK-13 cell monolayer cultured
in 96-well culture plate with MEM containing 2%FBS at
35˚C acquired the morphology of cell over-growth after 5 to
7-day cultivation (Figure 1B). The morphology of RK-13
over-growth was very similar to that of cells infected with
rubella virus (Figure 1C). The results showed the lower culture temperature we selected, the longer the RK-13 monolayer could maintain (data not shown). The RK-13 cells had
abnormal morphology included large plasma vesicles and

Figure 1. Phase contrast microscopic view of RK-13 monolayer infected with and without rubella virus. RK-13 cells were cultured in medium containing 2% FBS for 14 days at 33˚C with (C) and without rubella infection (A). Cell-overgrowth was appeared on RK-13 cells cultured in 2%
FBS/MEM for 7 days at 35˚C (B). Arrow, morphology of rubella viral CPE; arrowhead, morphology of cell-overgrowth. Bar = 40 µm.

Figure 2. RK-13 cell growth response to different culture conditions. Cells were initially plated at 1.3 × 104 per well. Cells were cultured with
MEM containing 2%FBS at 30, 33 and 35˚C for 14 days (A), or they were supplied with MEM containing 0.5, 1.0 and 2% FBS at 33 (B) for 14
days. Cell number was determined on Day 1, 3, 7, 10 and 14. Data are mean ± SD of triplicated determinations. , 35˚C and 2% FBS; , 33˚C
and 2% FBS; , 30˚C and 2% FBS; , 33˚C and 2% FBS; , 33˚C and 1.5% FBS; , 33˚C and 0.5% FBS. *, cell over-growth; , morphologic
abnormality; , cell death.
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elongated pseudopodia (data not shown) while they were cultured at 30˚C for 10 Days and were not even able to form a
confluent monolayer until the end of tests (Figure 2A). In
addition, the lower serum starvations than 2%FBS also led to
rounded sharp and dying at 33˚C incubation for 10 days
(Figure 3B). However, the initial plating numbers of RK-13
cells also influenced the monolayer stability besides serum
concentrations and culture temperatures. We tested several
plating numbers and found not more than 13,000 cells per
well was the suitable plating number for 14-day culture (data
not shown). We suggest that RK-13 cells keep their normal

Figure 3. Rubella viral CPE presentation on 10-fold serial dilutions of
rubella vaccine. Rubella vaccine sample was proceeding as 10-fold serial dilutions with 2%FBS/MEM. Each dilution of rubella inoculums
was added into a 96-well plate of RK-13 monolayer by 0.1 mL per well
with 10 duplicates. The cells were then incubated at 30 (A), 33 (B) and
35 (C)˚C for 14 days. Viral CPE was identified by phase-contrast
microscopic examination. The number of CPE per well appeared in
each dilution was recorded during Day 1 to Day 14. Data are mean of
total determinations. , 10-1 dilution; , 10-2 dilution; , 10-3 dilution; , 10-4 dilution.

morphology and physiological expression for testing periods
only under the conditions of 13,000 cells per well, 2% FBS/
MEM and 33˚C incubation.
To evaluate the effects of RA27/3 strain virus infection
under different inoculating/incubating temperatures, we conducted a series of in vitro CPE potency tests to compare the
speed of CPE presentation and data stability among the 30,
33 and 35˚C incubating conditions. The results showed the
rubella viral CPE of each diluted treatment appeared rapidly
and reached a maximum on Day 8 under 33˚C incubation
(Figure 3B). However, the CPE number appeared more slowly and only reached a maximum on Day 12 while the inoculum was incubated at 30˚C (Figure 3A). Although the numbers of viral CPE appeared most rapidly under the 35˚C incubating condition at 10-1 x dilution, the viral CPEs initially
appeared more slowly and variably at 10-2 x, 10-3 x and 10-4
x dilutions (Figure 3C). This finding was similar to the testing results of RK-13 cell culture conditions, that was, it also
supported that the condition of 33˚C and 2% FBS/MEM was
the most suitable for rubella viral CPE identification.
To validate the results from the potency tests under different incubating temperatures, we analyzed the experimental data with several statistical methods. According to the
ICH analytical procedure guideline(20), table two shows the
experimental design for testing method validation of rubella
vaccine potency. In this analytic matrix, the coefficient of
variation (C.V., also called relative standard deviation, RSD)
was used to estimate the repeatability for the triplicate of
each potency test. In addition, we used one-way analysis of
variation (one-way ANOVA) and Fisher’s protected least significant difference (FPLSD) multiple comparison analysis to
validate the accuracy and intermediate precision of total tests
among all incubating conditions. In our results of validating
analysis, the C.V. values of all potency tests were valid and
ranged from 0 to 11.54%. The C.V. values from the tests
under the 33˚C incubation were lower than ones from other
two conditions (from 0.45 to 7.32% and from 1.72 to
11.54%) and ranged from 0 to 5.51% (Table 3). These results
indicate that the 33˚C incubating condition provided the
highest repeatability in each of the triplicate tests. Table four
shows the results of FPLSD multiple comparison analysis
among the 10-times tests. There was no significant difference
among the average rubella potency under the 33˚C incubation. The difference among the tests was statistically significant (p < 0.05) under either the 30˚C or the 35˚C incubation.
In addition, the results of one-way ANOVA also showed that
there was no significant difference in the variance among 10times potency tests (p = 0.205) in 33˚C incubating conditions
(Table 5). However, the difference of variance among these
tests was statistically significant under either the 30 or the
35˚C incubation. The CPE method of rubella potency test
only conducted under the conditions of the 33˚C incubation
and 2% serum concentration could hold enough sensitivity,
accuracy and intermediate precision.
Because RK-13 monolayers infected with rubella virus
were protected against the infection of VSV, technicians
should avoid making a mistake about recognizing the real
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Table 2. Experimental design for the evaluation on the in vitro CPE assay system of live rubella virus vaccine
Incubating
In vitro CPE Assay for Rubella Vaccine
Conditions
Test 1
Test 2
---------Repeat 11
Repeat 21
---------Repeat 12
Repeat 22
---------FBS: 2%
Repeat 13
Repeat 23
---------Temp: 30˚C
Mean 1 (n=3)
Mean 2 (n=3)
---------SD
SD
---------C. V. (Repeatability)
C. V. (Repeatability)
---------FPLSD, N=X (Accuracy)
ANOVA (Intermediate Precision)
Mean 1 (n=3)
Mean 2 (n=3)
---------FBS: 2%
SD
SD
---------Temp: 33˚C
C. V. (Repeatability)
C. V. (Repeatability)
---------FPLSD, N=X (Accuracy)
ANOVA (Intermediate Precision)
Mean 1 (n=3)
Mean 2 (n=3)
---------FBS: 2%
SD
SD
---------Temp: 35˚C
C. V. (Repeatability)
C. V. (Repeatability)
---------FPLSD, N=X (Accuracy)
ANOVA (Intermediate Precision)
Table 3. The repeatability evaluation for the in vitro CPE assay system of live rubella virus vaccine
Incubating
Rubella Vaccine Potency (Log10CCID50/dose)
Conditions
Test
1
2
3
4
5
6
7
Mean
2.953
3.169
3.379
3.375
3.347
3.752
2.993
FBS: 2%
SD
0.216
0.171
0.060
0.107
0.160
0.168
0.112
Temp: 30˚C C. V.
7.32%
5.41%
1.76%
3.16%
4.78%
4.49%
3.74%
Mean
3.476
3.227
3.262
3.337
3.671
3.337
3.186
FBS: 2%
SD
0.056
0.028
0.088
0.174
0.048
0.174
0.122
Temp: 33˚C C. V.
1.63%
0.87%
2.71%
5.20%
1.31%
5.20%
3.82%
Mean
2.870
2.819
2.523
2.967
3.354
3.477
2.459
FBS: 2%
SD
0.280
0.301
0.160
0.282
0.102
0.060
0.114
Temp: 35˚C C. V.
9.77%
10.67%
6.34%
9.50%
3.03%
1.72%
4.62%

Test N
Repeat N1
Repeat N2
Repeat N3
Mean N (n=3)
SD
C. V. (Repeatability)

Mean N (n=3)
SD
C. V. (Repeatability)

Mean N (n=3)
SD
C. V. (Repeatability)

8
3.146
0.107
3.40%
3.217
0.117
5.51%
2.692
0.311
11.54%

9
3.333
0.015
0.45%
3.350
0.000
0.00%
3.308
0.313
9.47%

10
3.479
0.196
5.63%
3.320
0.109
3.30%
3.459
0.220
6.37%

Table 4. The results of FPLSD multiple comparison analysis among the different incubated temperature
Incubation Temperature
Rubella Vaccine Potency (Log10CCID50/dose)
30˚C Ranked Group
6
10
3
4
5
9
2
8
7
1
Mean
3.752
3.479
3.379
3.375
3.347
3.333
3.169
3.146
2.993
2.953
33˚C Ranked Group
5
1
9
4
6
10
3
2
8
7
Mean
3.671
3.476
3.350
3.337
3.337
3.320
3.262
3.227
3.217
3.186
35˚C Ranked Group
6
10
5
9
4
1
2
8
3
7
Mean
3.477
3.459
3.354
3.308
2.967
2.870
2.819
2.692
2.523
2.459
Means underlined by the same line were not significantly different (α = 0.05). The average potency from the 30˚C incubation among 10 tests were
ranked and grouped into 4 groups. The average potency from the 35˚C incubation among 10 tests were also ranked and grouped into 3 groups.
However, only the average potency from the 33˚C incubation were able to be pooled together. The results of 10 tests were homogeneous, that was,
the 33˚C incubating condition could provide highly testing accuracy.
Table 5. The one-way ANOVA table of the potency test validation for live rubella virus vaccines
Sum of Squares
df
Mean Square
Temp 30˚C
Between Tests
1.624
9
0.180
Within Tests
0.439
22
0.020
Total
2.062
31
Temp 33˚C
Between Tests
0.638
9
0.071
Within Tests
1.031
22
0.047
Total
1.669
31
Temp 35˚C
Between Tests
4.322
9
0.177
Within Tests
1.018
22
0.022
Total
5.340
31
a The rubella potency difference among 10 tests was statistically significant (α = 0.01).

F value
9.042

P value
0.0000137a

1.151

0.205

8.201

0.0000296a
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Figure 4. Phase contrast microscopic view of RK-13 monolayer infected with rubella virus and VSV. RK-13 cells cultured at 35˚C and formed the
overgrowth morphology on Day 7 (A). These cells were infected with VSV on Day 12 and formed cytopathic morphology after 24 hrs later (C).
Rubella virus infected RK-13 cells were co-infected with (D) and without VSV (B) in 2% FBS/MEM at 35˚C for 12~14 days. Arrow, morphology
of rubella viral CPE; arrowhead, morphology of cell-overgrowth. Bar = 40 µm.

Table 6. The paired T-test analysis of vaccine potency resulted from rubella virus infectivity and VSV interference infection
Incubating Temperature
30
33
35
VSV
Mean
3.2786
3.3202
3.3730
3.3868
2.9667
3.0502
Variance
0.0665
0.0595
0.0490
0.0460
0.1723
0.1825
dF
31
31
31
T value
-3.3146
-1.3945
-3.1917
P value
0.0023a
0.1731
0.0032a
a The difference between the potency results from CPE testing method and VSV interference testing method was statistically significant (α = 0.01).

rubella viral CPE and cell over-growth (Figure 4). Therefore,
we used the paired T-test to compare the difference between
the CPE results from microscopic examination under our
suggested conditions with and without the VSV interference
test. Table six shows there is no significant difference
between the potency results acquired from our suggested
testing condition and the VSV interference test. The differences between the CPE method and the VSV interference test
were statistically significant (p < 0.01) under other culture
conditions. Therefore, we suggest that the 2% of serum concentration and 33˚C incubating temperature could raise the
sensitivity, repeatability and accuracy of CPE method for
potency test of rubella vaccine. It also maintained the experimental precision similar to the results acquired from the
VSV interference test. Furthermore, the optimal testing conditions we provided for determination of rubella vaccine
potency enhanced the efficiency and precision, and these

conditions also reduced the infectious risk of VSV as well as
could promote the biosafety of laboratories. Although the
repeatability, accuracy, and intermediate precision are essential testing method performance characteristics, and successful assay validation provides the data to assess these validated parameters(20, 21), assays for the live virus vaccine potency (virus content) can result in highly variable results due to
the biological nature of the testing system. Furthermore, with
the traditional in vitro CPE assay for potency determination
of live rubella virus vaccine it is difficult to reduce assay bias
and maintain testing repeatability, and easily leads to false
positive or false negative potency results. Usually, variations
come from cells, viruses, and culture conditions which can
all significantly impact the results(7). However, we have the
responsibility to improve our testing accuracy, precision,
rapidity and sensitivity for vaccine surveillance and lot
release on the basis of our national authority.
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CONCLUTIONS
In this study, we evaluated the CPE method for rubella
potency test through statistical analysis. We found that serum
concentration of cell culture and incubating temperature were
the key factors influenced testing quality. Our results also
suggested that the CPE potency test of live rubella virus vaccine could obtain the most accurate and precise results under
the conditions of plating number of 13,000 cells/well, 2% of
serum concentration, and 33˚C of incubating temperature.
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